The BRAF ‐specific region suppresses cysteine‐rich domain–lipid interaction independently of canonical autoinhibition by the 14‐3‐3 dimer
Protein Science · 2026
DOI: 10.1002/pro.70419 ↗At a glance
Journal article in Protein Science, 2026. Written by Vasili Revazishvili and 8 co-authors. Institution: Department of Chemistry and Biochemistry, San Diego State University, San Diego, California, USA. Major MEDLINE topics: Proto-Oncogene Proteins B-raf, 14-3-3 Proteins, Protein Multimerization, Lipid Bilayers. Cited 3 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NIMHD NIH HHS, National Science Foundation, Prebys Foundation.
Abstract (original language)
BRAF is a serine/threonine kinase and a central effector of the mitogen‐activated protein kinase (MAPK) signaling pathway, frequently mutated in cancer. Its activation is tightly controlled by autoinhibitory mechanisms that regulate membrane recruitment and dimerization. The BRAF‐specific region (BSR), located at the N‐terminus, is known to promote isoform‐preferred RAS binding and facilitate dimerization with kinase suppressor of RAS (KSR), yet its role in regulating lipid interaction has remained unexplored. Here, we identify the BSR as a previously unrecognized inhibitory module that attenuates lipid binding by the cysteine‐rich domain (CRD). Using quantitative in vitro reconstitution with supported lipid bilayers and fluorescence microscopy, we demonstrate that the BRAF CRD exhibits high intrinsic affinity for phosphatidylserine‐rich membranes, but the inclusion of the BSR markedly reduces the membrane binding. We further demonstrate that the inhibitory function of the BSR correlates with its global electrostatic properties rather than a single defined sequence motif. This inhibitory effect of BSR was corroborated in live cells by quantifying plasma membrane localization of BRAF constructs, including the full‐length protein. When canonical autoinhibition of CRD—mediated by sequestration within the 14‐3‐3 dimer—is disrupted by oncogenic mutation or RAF inhibitor treatment, the BSR assumes a compensatory role in repressing CRD–lipid interaction. This additional regulatory layer provided by the BSR prevents RAS‐independent membrane recruitment under both physiological and pathological conditions.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Chemistry and Biochemistry, San Diego State University, San Diego, California, USA.
- Department of Biology, San Diego State University, San Diego, California, USA.
- The Smart Health Institute, San Diego State University, San Diego, California, USA.
ORCID profiles: Vasili Revazishvili, Bryn Baxter, Julian Grim, Ani Chakhrakia, Andres Jimenez Salinas, Kesaria Tevdorashvili, Angelica M Riestra, Young Kwang Lee
Funding
- NIMHD NIH HHS
- National Science Foundation
- Prebys Foundation
- Rees-Stealy Research Foundation
- Association for Women in Science-San Diego
- Conrad Prebys Foundation
- National Institute on Minority Health and Health Disparities
Cite
APA
Revazishvili, V., Morales, A., Baxter, B., Grim, J., Chakhrakia, A., Jimenez Salinas, A., Tevdorashvili, K., Riestra, A. M., & Lee, Y. K. (2026). The BRAF ‐specific region suppresses cysteine‐rich domain–lipid interaction independently of canonical autoinhibition by the 14‐3‐3 dimer. Protein Science. https://doi.org/10.1002/pro.70419
Vancouver
Revazishvili V, Morales A, Baxter B, Grim J, Chakhrakia A, Jimenez Salinas A, et al. The BRAF ‐specific region suppresses cysteine‐rich domain–lipid interaction independently of canonical autoinhibition by the 14‐3‐3 dimer. Protein Science. 2026. doi:10.1002/pro.70419
BibTeX
@article{Revazishvili2026,
author = {Revazishvili, Vasili and Morales, Alexia and Baxter, Bryn and Grim, Julian and Chakhrakia, Ani and Jimenez Salinas, Andres and Tevdorashvili, Kesaria and Riestra, Angelica M and Lee, Young Kwang},
title = {The BRAF ‐specific region suppresses cysteine‐rich domain–lipid interaction independently of canonical autoinhibition by the 14‐3‐3 dimer},
journal = {Protein Science},
year = {2026},
doi = {10.1002/pro.70419}
}
EUVIMED